NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that its CEO, Jeffrey Meckler will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference. The conference is being held on April 3 - 4, 2024 at Cooley Law, 55 Hudson Yards, New York, NY 10001.
Presentation Date: | April 3, 2024 | |
Time: | 9:55am ET | |
Webcast Link: | MedInvest Biotech & Pharma Conference Apr 3-4, 2024 | |
"We are pleased to participate in the MedInvest Biotech & Pharma Investor Conference hosted by Cooley Law," said Jeffrey Meckler. "We are looking forward to meeting with investors to update our progress on our innovative therapies that leverage the body's own immune system to revolutionize the treatment of cancer and viral infections."
Mr. Meckler will be available for one-on-one meetings throughout the conference.
For more information about the conference, please click below:
https://www.medinvestconferences.com
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication ...